HCA Healthcare, Inc. provides health care services in the United States through its subsidiaries. It owns, manages, and operates hospitals, ambulatory surgery centers, freestanding emergency and urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, rehabilitation and physical therapy centers, physician practices, home health agencies, hospices, outpatient physical therapy providers, and home and community-based services providers. Its general and acute care hospitals offer inpatient, intensive, cardiac, diagnostic, and emergency services, as well as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was formerly known as HCA Holdings, Inc., was founded in 1968, and is headquartered in Nashville, Tennessee.
HCA hit by uninsured surge, law firm probes; Q2 beat lifts shares
▼
Law firm investigations into HCA Three law firms opened investigations into whether HCA misled investors about its payer mix before cutting guidance. No lawsuit has been filed, but the probes add legal uncertainty and can weigh on the stock by raising the risk of future costs and management distraction.
New legal risk directly tied to HCA's guidance cut, affecting investor confidence.
▲
Q2 earnings beat estimates HCA reported second-quarter earnings of $7.59 per share, beating estimates by $0.09, on revenue of $20.23 billion, which topped expectations by $490 million. Same-facility admissions rose 2.5%. The beat shows the core business is still growing, which pushed the stock up over 5% on the day.
New positive earnings surprise that lifted the stock, showing underlying demand strength.
▼
Exchange headwind larger than expected HCA now expects a $1 billion to $1.2 billion hit from patients losing health insurance exchange coverage, as nearly all became uninsured rather than switching plans. This reduces revenue per visit and forced a cut to full-year profit guidance, pressuring the stock.
New detail on the size and cause of the guidance cut, a key negative driver.
◆
Surgery declines and cash flow drop Inpatient and outpatient surgeries fell 2.3% and 3.4%, partly from fewer elective procedures, and operating cash flow dropped 45% to $2.3 billion. Weaker surgery volumes and cash generation are warning signs, though HCA still approved over $7 billion in capital spending and bought back $2.1 billion of stock.
New operational weakness that offsets the earnings beat and could limit future growth.
Q3 2026
▼3▲1
HCA cuts guidance on coverage losses, but Q2 beat lifts shares
▼
Guidance cut on coverage losses HCA cut its 2026 profit guidance to $28.70–$30.50 per share, citing a $400 million hit from patients losing exchange coverage—now expected to reach $1–1.2 billion as most became uninsured.
This is the main negative driver of the period, directly reducing expected earnings.
▼
Worsening nursing shortage and legal probes A worsening nursing shortage (28% to 39%) raises labor-cost concerns, and three law firms are investigating whether HCA misled investors about its payer mix.
These add cost pressure and legal uncertainty, weighing on investor sentiment.
▼
Volume and cash flow decline Surgeries fell 2.3–3.4% and operating cash flow dropped 45%, signaling weaker demand and cash generation.
These operational metrics show underlying business deterioration.
▲
Q2 earnings beat and AI edge Q2 earnings beat estimates ($7.59/share, $20.23 billion revenue), lifting shares over 5%. UBS sees HCA's AI investments in denials and staffing as a durable edge over insurers, and positive NEJM CRISPR gene-therapy results strengthen its advanced-care reputation, though near-term earnings impact is limited.
This positive news offset the negative guidance and drove the stock higher.
News & notes movingHCA
United States
HCA▲
Community Health Systems Guides 2026 Revenue of $11.4-$11.6 Billion as Elective Demand Softens
Community Health Systems reported second-quarter 2026 same-store net revenues up 2.4% year over year and adjusted admissions up 2.9%, but roughly half of that admission growth came from uninsured patients, limiting the revenue benefit. Same-store net revenue per adjusted admission declined 0.5% on weaker service and payer mix, and same-store surgeries fell 0.1% with inpatient surgeries down 3.8% as orthopedic and cardiac procedures stayed soft. Adjusted EBITDA declined to $330 million in the second quarter from $380 million a year earlier, also reflecting divestitures and differences in state-directed payment benefits, while operating cash flow was $87 million. The company now expects 2026 revenues of $11.4-$11.6 billion and adjusted EBITDA of $1.30-$1.375 billion. Among peers, HCA Healthcare posted same-facility admissions up 2.5% and revenue per equivalent admission up 6.4%, while Tenet Healthcare reported net operating revenues up 6% and same-hospital net patient service revenue per adjusted admission up 3.3%.
CYH · Capital · Negative Q2 adjusted EBITDA fell to $330M from $380M and 2026 guidance of $11.4-$11.6B revenue / $1.30-$1.375B EBITDA reflects softening elective demand and weaker payer mix.
HCA · Demand · Positive HCA posted same-facility admissions up 2.5% and revenue per equivalent admission up 6.4%, cited as a stronger peer comparison.
THC · Demand · Positive Tenet reported net operating revenues up 6% and same-hospital net patient service revenue per adjusted admission up 3.3%, cited as a stronger peer comparison.
HCA Healthcare Faces Payer-Mix Pressure as Exchange Admissions Fall 15%
HCA Healthcare is navigating a shifting service and payer mix that is offsetting healthy demand, with same-facility exchange-related equivalent admissions falling 15% while uninsured equivalent admissions rose 15% in the second quarter of 2026. Same-facility equivalent admissions climbed 2.7% year over year and emergency room visits rose 3.6%, while same-facility equivalent admissions among insured patients excluding exchange plans grew 3.2%. Adjusted EPS advanced 11% year over year, helped by higher admissions, better expense performance and Medicaid supplemental payments, but inpatient and outpatient surgeries declined 2.3% and 3.4% respectively as weaker elective demand weighed on procedure volumes. HCA is leaning on its resiliency program to control costs through digital tools, global capabilities and workforce initiatives, and expects those efforts to improve cost trends in the second half of 2026 and into 2027. The Zacks Consensus Estimate for HCA Healthcare's 2026 earnings is $29.42 per share, implying 4.3% growth from the year-ago period, and the stock carries a Zacks Rank #3 (Hold).
HCA Healthcare Completes Acquisition of College of Health Care Professions
HCA Healthcare has completed its previously announced acquisition of The College of Health Care Professions. The Nashville-based hospital operator said the deal builds on its longstanding commitment to healthcare education and on decades of collaboration with CHCP through program advisory boards, clinical sites and career placement. CHCP serves more than 8,000 students at 10 campuses across Texas and through online programs, offering more than 20 accredited healthcare programs, and has helped prepare more than 52,000 students for healthcare careers since its founding in 1988. Eric Bing will continue to lead CHCP as Chancellor and CEO, and the college will preserve its mission, programs and focus on adult learners. HCA Healthcare, founded in 1968, comprises 190 hospitals and approximately 2,600 ambulatory sites of care in 19 states and the United Kingdom, and supports more than 365 Graduate Medical Education programs across 87 hospitals.
HCA · Capital · Positive HCA Healthcare completed its acquisition of The College of Health Care Professions, expanding its healthcare education footprint.
The College of Health Care Professions · Capital · Positive CHCP was acquired by HCA Healthcare, which will preserve its mission, programs and leadership.
HCA Healthcare has cut its full-year 2026 earnings guidance, citing a worsening payer mix after Affordable Care Act subsidy expirations, softer high-margin elective surgeries, and rising costs that also prompted targeted layoffs and at least one hospital divestiture. The company estimates a US$400 million quarterly revenue impact from payer shifts and faces an ongoing legal review of prior disclosures. These actions highlight how policy-driven reimbursement changes can quickly pressure hospital profitability and corporate staffing decisions. The guidance reset and payer mix pressures could alter HCA's previously optimistic investment narrative, which projects $88.7 billion revenue and $7.2 billion earnings by 2029, requiring 4.4% yearly revenue growth and about a $0.4 billion earnings increase from $6.8 billion today. Analysts' cautious forecasts already assumed only about 2.8% annual revenue growth and earnings of roughly US$6.6 billion by 2029, and this payer mix shock could push those views further.
HCA Healthcare Appoints New Clinical Chief and Creates Ambulatory Operations Group
HCA Healthcare has appointed Michael Schlosser as executive vice president and chief clinical officer and created a new Ambulatory Operations Group led by Charles Gressle, consolidating oversight of clinical services, digital transformation, and more than 2,700 outpatient facilities as part of a leadership realignment taking effect in 2026. Schlosser will simultaneously run the Clinical Services Group and digital transformation and clinical informatics efforts, tightening the link between care quality, technology deployment, and operational decision-making. The reorganization does not materially change the near-term story, which still turns most on payer mix pressures and Medicaid-related reimbursement risk, with HCA reaffirming 2026 guidance that projects net income of US$6.3 billion to US$6.7 billion. Some analysts had already assumed HCA could reach about US$90.0 billion of revenue and US$7.6 billion of earnings, and the leadership changes may either strengthen that upside or test it if payer mix and exchange-related risks prove tougher than expected.
Bragar Eagel & Squire Investigates HCA Healthcare on Behalf of Stockholders
Bragar Eagel & Squire, P.C. is investigating potential claims against HCA Healthcare, Inc. on behalf of HCA stockholders. The investigation concerns whether HCA violated federal securities laws or engaged in other unlawful business practices. On July 14, 2026, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in payer mix that impacted revenue by approximately $400 million in the second quarter. Following that news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share. Stockholders who purchased or acquired HCA shares and suffered a loss are encouraged to contact the firm.
Pomerantz Law Firm Investigates HCA Healthcare Over Securities Fraud Claims
Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On July 14, 2026, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in payer mix that impacted revenue by approximately $400 million in the second quarter. Following that news, HCA’s stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, extension 7980.
HCA · Capital · Negative HCA lowered its 2026 profit guidance due to unfavorable payer mix, causing a 6.95% stock drop and triggering a securities fraud investigation.
HCA Healthcare reported second-quarter revenue of $20.23 billion, beating analyst estimates of $19.76 billion, while adjusted EBITDA of $4.03 billion also exceeded expectations. However, the company lowered its full-year EPS guidance to $29.60 at the midpoint, missing analyst estimates by 1.2%, as an unexpected increase in uninsured patients following the expiration of enhanced premium tax credits pressured margins. CEO Samuel N. Hazen noted that adjusted admissions for patients formerly covered by health insurance exchanges declined by 15%, with nearly all of those patients becoming uninsured. CFO Michael A. Marks explained that the updated guidance reflects this payer mix shift, which was a bigger driver than initially assumed. Analysts on the call also questioned management about declines in elective surgeries, cost trends, and capital allocation, with Hazen attributing elective softness to affordability challenges and loss of coverage.
HCA Healthcare projects 2026 revenue of $77 billion to $79.5 billion amid up to $1.2 billion exchange headwind
HCA Healthcare has issued revised 2026 guidance with revenue between $77 billion and $79.5 billion and diluted earnings per share between $28.70 and $30.50. The updated outlook reflects a larger-than-expected headwind from health insurance exchanges, now estimated at a negative $1 billion to $1.2 billion, as nearly all patients losing exchange coverage became uninsured rather than shifting to other plans. This payer mix shift had an unfavorable impact on adjusted EBITDA of approximately $400 million in the second quarter, partially offset by a $400 million incremental net benefit from Medicaid Supplemental Payment Programs, including $540 million related to a recently approved Florida program. Second-quarter admissions rose 2.5% and equivalent admissions increased 2.7%, while emergency room visits grew 3.6%, though inpatient and outpatient surgeries declined. The company also approved more than $7 billion in capital expenditures to come online over the next three years and repurchased $2.064 billion of shares during the quarter.
HCA Healthcare beats Q2 earnings estimates on strong admissions, revises 2026 outlook
HCA Healthcare reported second-quarter 2026 adjusted earnings per share of $7.59, beating the Zacks Consensus Estimate of $7.57 and rising 11% year over year. Revenues grew 8.7% to $20.2 billion, matching estimates, driven by a 2.7% increase in same-facility equivalent admissions and a 6.4% rise in revenue per equivalent admission. However, same-facility inpatient surgeries fell 2.3% and outpatient surgeries dropped 3.4%, while operating expenses climbed 9.8% to $16.2 billion. The company revised its full-year 2026 revenue guidance to a range of $77.0 billion to $79.5 billion, narrowed its adjusted EBITDA forecast to $15.4 billion to $16.1 billion, and lowered its diluted EPS outlook to $28.70 to $30.50.
Portnoy Law Firm investigates HCA Healthcare for possible securities fraud
The Portnoy Law Firm has initiated an investigation into HCA Healthcare for possible securities fraud and may file a class action on behalf of investors. The investigation follows HCA's July 14, 2026 press release that significantly downgraded its full-year 2026 earnings outlook, citing an adverse shift in payer breakdown due to a surge in uninsured patient visits that erased roughly $400 million in quarterly revenue. HCA revised its full-year earnings forecast to a range of $28.70 to $30.50 per share, tightened revenue guidance to between $77 billion and $79.5 billion, and scaled back adjusted EBITDA expectations to $15.4 billion to $16.1 billion. Following these disclosures, HCA's stock fell $27.14 per share, or 6.95%, to close at $363.60 on July 14, 2026. Investors are encouraged to contact the firm to discuss their legal rights.
HCA · Capital · Negative HCA downgraded its full-year 2026 earnings outlook due to a surge in uninsured patient visits, erasing $400 million in quarterly revenue.
Bragar Eagel & Squire Investigates HCA Healthcare on Behalf of Stockholders
Bragar Eagel & Squire, P.C. has launched an investigation into HCA Healthcare, Inc. on behalf of its stockholders. The investigation concerns whether HCA violated federal securities laws or engaged in other unlawful business practices. The inquiry follows HCA's July 14, 2026 announcement of preliminary second-quarter 2026 results, in which the company sharply lowered its full-2026 profit guidance, citing an unfavorable shift in payer mix that impacted revenue by approximately $400 million in the quarter. On that news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share. The law firm encourages investors who purchased or acquired HCA shares and suffered a loss to contact partners Brandon Walker or Melissa Fortunato to discuss their legal rights.
Kirby McInerney investigates HCA Healthcare for potential securities fraud
Kirby McInerney LLP announced an investigation into HCA Healthcare over potential violations of federal securities laws. The investigation follows HCA Healthcare's July 14, 2026, preliminary second-quarter results, which sharply lowered full-year 2026 profit guidance due to an unfavorable payer mix shift driven by increased uninsured volume, impacting revenue by approximately $400 million in the quarter. The company now forecasts 2026 earnings between $28.70 and $30.50 per share, narrowed its revenue target to $77 billion to $79.5 billion, and adjusted its EBITDA target to between $15.4 billion and $16.1 billion. On the news, HCA Healthcare's stock fell $27.14 per share, or 6.95%, to close at $363.60. The law firm is investigating whether senior management engaged in unlawful business practices, and no lawsuit has been filed at this stage.
HCA · Capital · Negative HCA lowered full-year profit guidance due to unfavorable payer mix shift, causing stock to fall 6.95%; law firm investigates potential securities fraud.
HCA Healthcare, UnitedHealth, CrowdStrike, RXO, and Enovis make big moves this week
Several stocks made notable moves this week. HCA Healthcare fell 6.7% on Tuesday after releasing preliminary second-quarter results and cutting its full-year 2026 profit guidance. UnitedHealth rose 5.1% on Thursday after reporting second-quarter earnings that surpassed Wall Street expectations, driven by improved profitability. CrowdStrike gained 9.8% on Tuesday after U.S. and international security agencies issued a joint warning about Russian state-sponsored cyber threats targeting critical infrastructure. RXO rose 4.2% on Monday after Stifel raised its price target on the stock to $30 from $22 while maintaining a Buy rating. Enovis rose 3.6% on Monday after announcing the U.S. launch of CT-RevitL, a new veterinary laser therapy system from its Companion Animal Health business.
GE HealthCare Technologies faces fresh valuation test after Mayo Clinic trial tie-up
GE HealthCare Technologies is under fresh valuation scrutiny following a new research collaboration with Mayo Clinic on the MI-BET theranostics trial for advanced prostate cancer. The stock has fallen 13.66% over the past 90 days to a recent price of US$63.20, with a one-year total shareholder return decline of 16.09%, amid slower reported order growth and sector concerns after HCA Healthcare's update on surgery volumes. The most followed narrative points to a fair value of US$79.72, implying the stock is 20.7% undervalued, anchored in long-term earnings and margin assumptions driven by a pipeline of products including Radiopharmaceuticals, Total Body PET, and Photon Counting CT. However, the company still faces tariff and China regulatory risks, and any stumble in new product execution could challenge the undervaluation story.
HCA Healthcare Stock Still Trades at a Discount Despite 52% Five-Year Return
HCA Healthcare stock screens as undervalued across all six valuation measures on Simply Wall St, even after delivering a 52.3% return over the past five years. The company trades at a price-to-earnings ratio of about 11.9 times, well below the broader healthcare industry average of around 25.1 times and the peer group average of roughly 15.0 times. Simply Wall St's fair multiple framework suggests a P/E closer to 26.7 times given HCA Healthcare's growth, margins, size, and risks, implying a wide discount. The investment case is supported by expectations around the company's use of scale and artificial intelligence tools to support care quality, while a rising load of uninsured patients and union-related staffing pressures may weigh on profitability and investor confidence. The key question is whether HCA Healthcare can sustain earnings quality well enough for the valuation gap to close rather than become a longer-term value trap.
HCA · Capital · Positive Stock is undervalued per multiple valuation measures, trading at a P/E discount to industry and peers, with analyst fair value suggesting upside.
HCA Healthcare lowered its full-year 2026 earnings guidance due to a payer mix shift toward more uninsured patients following changes in health insurance exchange coverage, sending its stock down 14.1%. The company reported preliminary second-quarter 2026 revenue of about US$20.23 billion and net income of about US$1.70 billion, but now expects full-year net income between US$6.3 billion and US$6.7 billion, down from prior expectations. HCA said the unfavorable impact on income before taxes from the payer mix shift will be only partly offset by incremental benefits from Medicaid Supplemental Payment Programs, prompting tighter full-year revenue and earnings ranges. The revision brings earlier concerns about Medicaid volumes, reimbursement complexity, and supplemental program variability into sharper focus, suggesting these policy-driven items may matter more to near-term outcomes than cost savings or expansion projects.
Universal Health Services shares fall 5.6% amid nursing shortage and HCA profit warning
Shares of Universal Health Services fell 5.6% to close at $144.23 after a reported surge in nursing shortages and a profit forecast cut by peer HCA Healthcare pressured the hospital sector. The nursing shortage rate reportedly jumped from 28% to 39%, raising expectations of higher labor costs and tighter margins. HCA, the largest for-profit U.S. hospital operator, lowered its profit outlook due to an increase in uninsured patients following losses in Obamacare coverage. Universal Health Services stock is down 34.6% year-to-date and trades 41.1% below its 52-week high of $244.18 from November 2025.
UHS · Supply · Negative Nursing shortage rate surged from 28% to 39%, raising expectations of higher labor costs and tighter margins for Universal Health Services.
HCA · Demand · Negative HCA lowered profit outlook due to increase in uninsured patients after Obamacare coverage losses, indicating weaker demand for hospital services.
IBM plunges 25% on weak preliminary earnings while Goldman Sachs jumps 7%
IBM plunged 25% after issuing weaker-than-expected preliminary second-quarter earnings, expecting a profit of $2.93 per share excluding certain items versus the $3.01 per share analysts polled by FactSet had anticipated. Goldman Sachs jumped 7% after posting second-quarter earnings of $20.98 per share, well above the $14.48 LSEG consensus estimate, with revenue of $20.34 billion also topping the $16.13 billion expected. CleanSpark surged 11% after securing a 20-year data center lease in Georgia totaling $6.6 billion in contracted revenue. HCA Healthcare fell more than 7% after lowering its full-year earnings guidance to between $28.70 and $30.50 per share, down from a prior forecast of $29.10 to $31.50 per share, and also reduced the top end of its 2026 revenue outlook. JPMorgan Chase rose 2% after reporting second-quarter earnings of $6.14 per share on revenue of $58.02 billion, exceeding LSEG estimates of $5.85 per share on $50.19 billion in revenue. Bank of America added 2% after beating expectations with earnings of $1.21 per share on revenue of $31.7 billion, compared to the $1.13 per share and $30.72 billion consensus. Wells Fargo fell 3% despite posting earnings of $2.00 per share on revenue of $22.62 billion, above the $1.72 per share and $21.84 billion expected. Citigroup fell 5% even after logging its best quarterly revenue in a decade, with earnings of $3.15 per share on revenue of $24.77 billion, surpassing the $2.74 per share and $23.74 billion estimates. Apple dipped 1% after KeyBanc downgraded the stock to underweight from sector weight with a $250 price target, citing potential pressure from consumer spending pullbacks. O-I Glass slumped 8% after a double downgrade to underperform from buy at Bank of America, which pointed to a recent 20% rally, challenging glass demand, and other headwinds. LM Ericsson dropped 13% after reporting revenue of 52.70 billion Swedish kronor, missing the 53.94 billion consensus estimate, though adjusted gross margin of 48.4% topped the 47.8% expected. MBX Biosciences tumbled 8% after announcing CEO Kent Hawryluk stepped down effective immediately, to be replaced by Executive Chairman Steve Hoerter.
Right Tail Capital Initiates Position in HCA Healthcare, Citing Dominant Market Position and Reasonable Valuation
Right Tail Capital has established a position in HCA Healthcare, the largest for-profit hospital operator in the United States, according to the firm's Q2 2026 investor letter. The investment firm highlighted HCA's combination of dominant local market positions, outstanding operational execution, disciplined capital allocation, and resilient demand, noting it trades at a reasonable valuation. HCA operates 190 hospitals and more than 2,500 outpatient sites across 19 states and the U.K., serving 47 million patients annually, and generates more than $70 billion in annual revenue with a market capitalization exceeding $100 billion. The company holds the number one or number two market share position in roughly 80% of its markets, primarily in high-growth Sunbelt states like Florida and Texas, creating a powerful flywheel that attracts physicians and patients while improving negotiating leverage with insurers.
HCA Healthcare Could Be 35% Undervalued Following Downgrades and Index Exits
HCA Healthcare may be 35% undervalued according to a widely followed narrative, which sets a fair value of $629.14 against a last close of $410.61. The stock has fallen 19.04% over the past 90 days and 12.71% year to date, underperforming the S&P 500, amid a Barclays downgrade and index removals. The narrative assumes steady revenue expansion, resilient margins, and disciplined future earnings, though risks include elevated labor costs and tighter reimbursement terms. Long-term holders have still seen a 95.75% total return over five years.
HCA · Capital · Positive Article claims HCA is 35% undervalued with a fair value of $629.14, implying upside despite recent downgrades and index exits.
HCA Healthcare Stock Falls 11.6% Over Six Months, Trades at 13.5× Forward P/E
HCA Healthcare shares have dropped 11.6% over the past six months to $423.55, underperforming the S&P 500's 9% gain. The company generated $76.39 billion in revenue over the last twelve months, giving it significant scale and supplier negotiating leverage in the hospital industry. Earnings per share grew at a 19.9% compound annual rate over five years, outpacing 7.7% annualized revenue growth, while its five-year average return on invested capital reached 28.8%. The stock now trades at 13.5 times forward earnings.
Wall Street analysts issue upgrades, downgrades, and initiations on Alcoa, Occidental Petroleum, PayPal, and others
Wall Street analysts issued a flurry of rating changes and initiations on Wednesday, July 8, 2026. Among the notable upgrades, Evercore ISI raised Occidental Petroleum to Outperform from In Line and lifted its price target to $65 from $58, while Goldman Sachs upgraded Dollar Tree to Neutral from Sell with a $155 target. On the downgrade side, Morgan Stanley cut Alcoa to Equal Weight from Overweight and slashed its price target to $53 from $79, and Barclays downgraded HCA Healthcare to Equal Weight from Overweight, reducing its target to $179 from $238. In new coverage, Barclays initiated PayPal with an Underweight rating and a $42 target, while DA Davidson started Pinterest with a Buy rating and a $26 target.
HCA Healthcare Identified as Value Stock to Buy, Charter and Avnet Flagged as Sells
StockStory identifies HCA Healthcare as a value stock offering a compelling risk-reward profile, while Charter and Avnet face challenges. HCA Healthcare, trading at $410.41 per share with a forward P/E of 12.8x, benefits from a dominant market position with $76.39 billion in revenue, share buybacks boosting earnings per share growth, and market-beating returns on capital. Charter, at $136.85 and a forward P/E of 3.1x, struggles with underwhelming internet subscriber numbers and stagnant returns on capital. Avnet, at $82.19 and a forward P/E of 11.5x, saw flat sales and a 17.7% annual decline in earnings per share over two years, with a negative free cash flow margin limiting its flexibility.
AVT · Capital · Negative Avnet reported flat sales and a 17.7% annual decline in EPS over two years, with negative free cash flow margin.
CHTR · Demand · Negative Charter struggles with underwhelming internet subscriber numbers and stagnant returns on capital.
HCA · Capital · Positive HCA Healthcare is identified as a value stock with a dominant market position, share buybacks boosting EPS, and market-beating returns on capital.
HCA's Gene Therapy Milestone Could Drive Long-Term Growth
HCA Healthcare is expanding its advanced medicine footprint after researchers from its Sarah Cannon Transplant and Cellular Therapy Program published encouraging findings in The New England Journal of Medicine. The study found that the CRISPR gene-editing therapy, exa-cel, successfully treated children aged 5 to 11 with severe sickle cell disease and transfusion-dependent beta thalassemia, marking the first published clinical study of the therapy in this young patient group. All eligible children with beta thalassemia became transfusion-independent for at least 12 months, and children with sickle cell disease remained free of severe pain crises over the same period. HCA is now expanding access to FDA-approved gene-editing therapies through specialized pediatric programs across its network. While the study is unlikely to materially impact near-term earnings, it reinforces HCA's growing role in advanced specialty care and highlights the strength of its clinical research platform.
Universal Health Services Leads Hospital Chains in Q1 with Strong Revenue Growth
Universal Health Services reported first-quarter revenues of $4.50 billion, up 9.6% year on year and exceeding analyst expectations by 2.4%, making it the best performer among the four hospital chains tracked. The group overall posted mixed results, with aggregate revenues beating consensus estimates by 0.7% but next-quarter revenue guidance coming in 2.7% below expectations. Tenet Healthcare's revenue of $5.37 billion met estimates, while Acadia Healthcare's $828.8 million exceeded by 0.6% and HCA Healthcare's $19.11 billion matched expectations. Despite the beats, share prices across the group have fallen an average of 9% since reporting, with Universal Health Services down 18.7% and HCA Healthcare down 17.5%.
HCA Healthcare Announces NEJM Study on CRISPR Therapy for Children with Blood Disorders
HCA Healthcare announced new research published in The New England Journal of Medicine showing promising results from a CRISPR-based gene-editing therapy in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. The study, led by Dr. Haydar Frangoul of HCA Healthcare's TriStar Centennial Children's Hospital, is the first published data evaluating exagamglogene autotemcel in this age group. Among participants followed long enough to assess primary endpoints, all eight children with beta thalassemia achieved transfusion independence for at least 12 months, and all eight with sickle cell disease remained free from severe vaso-occlusive crises for at least 12 months. The therapy is currently FDA-approved for patients ages 12 and older, and these findings suggest potential for earlier intervention before cumulative organ damage occurs. The study was sponsored by Vertex Pharmaceuticals and involved 26 children across two phase 3 trials.
TD Cowen lowered its price target on HCA Healthcare to $431 from $500 while maintaining a Buy rating. The firm reduced its 2026 and 2027 growth assumptions after a May hospital survey indicated flat year-over-year revenue, with weaker surgical volumes partially offset by growth in medical volumes. Separately, HCA Healthcare announced an agreement to acquire The College of Health Care Professions, which serves over 8,000 students annually across 10 Texas campuses and online.
Three Stocks to Buy on the Dip and Hold for a Decade
HCA Healthcare, MercadoLibre, and Visa are three stocks worth buying on the dip and holding for a decade, according to an analysis. HCA Healthcare has seen its shares fall due to economic challenges, but its leadership in the healthcare facility industry, increasing market share, and secular tailwinds like an aging population make it attractive. MercadoLibre's stock has underperformed as it invests heavily in financial services and e-commerce initiatives, but these moves could pay off long-term by tapping into underbanked populations and expanding its ecosystem. Visa faces antitrust lawsuits and a proposed bill targeting its duopoly with Mastercard, yet its strong financial results, network effects, and global shift to digital payments suggest the headwinds are already priced in.
Digital Finance & Tokenization › Payments Modernization & Rails ▼Regulation
Aging Population › Senior Care ▲Demand
HCA · Demand · Positive Aging population and increasing market share provide secular tailwinds for HCA Healthcare.
MELI · Capital · Neutral Heavy investments in financial services and e-commerce are weighing on near-term performance but could pay off long-term.
V · Regulation · Neutral Antitrust lawsuits and a proposed bill targeting its duopoly are headwinds, but strong financials and network effects suggest they are priced in.
HCA Stock's Quiet Compounding Widens Gap Between Earnings and Revenue Growth
HCA Healthcare's earnings per share have compounded at 13.3% annually over the past three years, far outpacing its 7.9% revenue growth rate, as operating margin expansion and aggressive share buybacks magnify per-share profits. The company's operating margin rose from 14.6% two years ago to 15.7% over the last twelve months, while a 19.3% reduction in outstanding shares over three years concentrated earnings among fewer shares. Despite revenue growth slowing to 6.7% in the last year, the stock trades at a trailing price-to-earnings multiple of 12.7, in the lower half of its 10-year range of 7.6 to 17.6, suggesting the market may be overlooking the earnings compounding engine.
HCA's chief clinical officer to step down after four years
HCA Healthcare's chief clinical officer Dr. Michael Cuffe will step down at the end of August, the for-profit hospital operator disclosed in a securities filing. Cuffe has led clinical operations since 2022 and will remain as an executive consultant until February to assist with the transition. He joined HCA in 2011 and oversaw clinical quality, nursing, care transformation, and clinical informatics across nearly 190 hospitals in 19 states and the U.K. Details on his successor will be released at the appropriate time, a spokesperson said.
UBS says hospitals may gain more from AI than health insurers
UBS analysts say hospitals could build a more durable competitive advantage from artificial intelligence than health insurers, even as AI becomes a core operating layer across healthcare. Analyst A.J. Rice notes that while managed-care companies like UnitedHealth Group, Elevance Health, Humana, Cigna, and Centene are deploying AI for claims processing, prior authorization, and customer service, those efficiency gains are highly replicable and likely to be competed away through pricing or benefit enhancements. In contrast, large for-profit hospital operators such as HCA Healthcare, Tenet Healthcare, and Universal Health Services are using AI for revenue cycle management, denial appeals, and staffing optimization, and may maintain a multiyear lead over slower-moving nonprofit systems. UBS highlights that Universal Health Services generated approximately $50 million in annualized additional revenue from an AI coding platform, while HCA is using AI to fight claim denials and optimize nurse staffing with a Palantir-built platform. The report concludes that AI will improve profitability unevenly, with hospitals better positioned to retain gains and expand margins over time.
Artificial Intelligence › AI Applications & Copilots ▲Competition
HCA · Technology · Positive UBS highlights HCA's AI use for claim denials and nurse staffing, suggesting durable competitive advantage and margin gains.
UHS · Technology · Positive UBS highlights Universal Health Services' $50M annualized revenue from AI coding platform.
THC · Technology · Positive UBS says hospitals like Tenet may build durable AI advantage, improving profitability.
CI · Competition · Negative UBS says insurers' AI efficiency gains are replicable and will be competed away, limiting margin expansion.
CNC · Competition · Negative UBS says insurers' AI efficiency gains are replicable and will be competed away, limiting margin expansion.
ELV · Competition · Negative UBS says insurers' AI efficiency gains are replicable and will be competed away, limiting margin expansion.
USA